Paediatrics Search
Paediatrics Paediatrics
bronchiolitis
BRONCHIOLITIS
Bronchiolitis is a clinical diagnosis preceding upper respiratory illness and/or rhinorrhea.
Signs of respiratory illness which may include wheezing, retractions, oxygen desaturation, color change, nasal flaring.
There is also presence of apnea especially in premature or low birthweight infants, signs of dehydration and exposure to persons with viral upper respiratory infections.
Symptoms are usually worst on the 3rd-5th day of illness and then improve gradually.
Drug Information

Indication: Management of reversible bronchospasm associated w/ obstructive airway disease in patients who require more th...

Indication: Tab/Syr Relief of all bronchial asthma, chronic bronchitis & emphysema. Evohaler Relief & prevention o...

Indication: Acute & chronic bronchopulmonary diseases associated w/ abnormal mucus secretion & impaired mucus tran...

Indication: Acute & chronic diseases of the resp tract especially chronic bronchitis, asthmatoid bronchitis, bronchial...

Indication: Asthalin Routine management of chronic bronchospasm unresponsive to conventional therapy. Treatment of acute s...

Axcel Dextrozine
dextromethorphan hydrobromide + promethazine hydro...

Indication: Relief of congestion & dry irritating cough eg, those associated w/ common cold, upper resp tract infectio...

Indication: Relief of bronchospasm in asthma, chronic bronchitis, other conditions involving airways obstruction.

Indication: Resp disorders associated w/ viscid mucus.

Indication: Symptomatic relief & prevention of asthma.

Indication: Relief & prevention of asthma symptoms.

1  /  7
1  /  7
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Could immunotherapy delay T1D diagnosis?
Roshini Claire Anthony, 27 Jun 2019

A 2-week course of the immunotherapy drug teplizumab delayed the onset of type 1 diabetes (T1D) in individuals at high risk for the condition, according to a phase II trial conducted by the TrialNet Study Group and presented at ADA 2019.